A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia

Chang Gung Medical Journal

Volumn 34, Issue 1, 2011, Pages 50-56

  Huang, Yu Shu ^a   Hsu, Shih Chieh ^a   Liu, Shen Ing ^c   Chen, Chih Ken ^b,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Hypnotics; Insomnia; Non benzodiazepine; Sleep latency

Indexed keywords

ZALEPLON; ZOLPIDEM;

ADULT; ANXIETY; ARTICLE; BEDTIME DOSAGE; CAUSE OF DEATH; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; LATENT PERIOD; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP TIME; TRAFFIC ACCIDENT; TREATMENT DURATION; URINARY TRACT INFECTION; WAKEFULNESS;

ACETAMIDES; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRIMIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 79952835153     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 2000;23:243-308.
2. World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: The American Psychiatric Association, 2000.
4. Terzano M, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261-82.
5. Elie R, Rither E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel non-benzodiazepine hypnotic. J Clin Psychiatry 1999;60:536-44.
6. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995;29:142-53.
7. Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med 2006;2:417-23.
8. Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 2004;19:305-22.
9. Allen D, Curran HV, Lader M. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993;45:313-20.
10. Allain H, Bentué-Ferrer D, Breton SL, Polard E, Gandon JM. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. Hum Psychopharmacol 2003;18:369-74.
11. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, A novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20.
12. Roehrs T, Vogel G, Roth T. Rebound insomnia: its determinants and significance. Am J Med 1990;88(3A):39S-42S.
13. Kales A, Scharf MB, Kales JD, Soldatos CR. Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA 1979;241:1692-5.
14. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 2000;15:141-52.
15. Bartholini G. Growing aspects of hypnotic drugs. In: Sauvanet JR, Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders. New York: Raven Press, 1988:1-9.
16. Mendelson WB, Jain B. An assessment of short-acting hypnotics. Drug Saf 1995;13:257-70.
17. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 1995;51:205-23.
18. Pandi-Perumal SR, Verster JC, Kayumov L, Lowe AD, Santana MG, Pires ML, Tufik S, Mello MT. Sleep disorder, sleepiness and traffic safety: a public health menace. Braz J Med Biol Res 2006;39:863-71.
19. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313:35-42.